AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories.
The Nutritional Products segment provides pediatric and adult nutritional products.
The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Country | United States |
IPO Date | Mar 17, 1980 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 114,000 |
CEO | Robert B. Ford |
Contact Details
Address: 100 Abbott Park Road North Chicago, Illinois United States | |
Website | https://www.abbott.com |
Stock Details
Ticker Symbol | ABT |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000001800 |
CUSIP Number | 002824100 |
ISIN Number | US0028241000 |
Employer ID | 36-0698440 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Robert B. Ford | Chairman of the Board, President & Chief Executive Officer |
Philip P. Boudreau | Chief Financial Officer & Executive Vice President of Finance |
Sabina Ewing | Senior Vice President of Business & Technology Services and Chief Information Officer |
Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products |
Erica L. Battaglia | Vice President and Chief Ethics & Compliance Officer |
Hubert L. Allen J.D. | Executive Vice President, General Counsel & Secretary |
Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices |
Mary K. Moreland | Executive Vice President of Human Resources |
Melissa Brotz | Senior Vice President of Global Marketing & External Affairs |
Michael Comilla | Vice President of Investor Relations. |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Jan 03, 2025 | 4 | Filing |
Nov 15, 2024 | 8-K | Current Report |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 23, 2024 | 4 | Filing |
Oct 16, 2024 | 8-K | Current Report |
Oct 01, 2024 | 4 | Filing |
Oct 01, 2024 | 4 | Filing |